International audienceAcute Graft-Versus-Host Disease (aGVHD), mediated by CD4(+) and CD8(+) effector T cells, is a life-threatening complication in hematopoietic stem cell (HSC) transplantation. Naturally-occurring CD4(+)CD25(hi)(Foxp3(+)) regulatory T cells (T(reg)) have been shown to modulate tolerance to aGVHD in murine graft models. In this report, we investigated their role in the prevention of aGVHD in patients transplanted with bone-marrow-derived HSC. When CD4(+)CD25(hi)Foxp3(+) T cells were isolated from bone-marrow grafts, they showed no suppressive activity. The analysis of their function in patients suffering from aGVHD after transplantation revealed a gain of suppressive activity indicating their inability to control the aGVHD...
International audienceThymus-derived regulatory T lymphocytes of CD4(+)CD25(+) phenotype regulate a ...
AbstractDonor bone marrow (BM)-derived CD4+CD25+ regulatory T cells, maturing in the host thymus, ar...
AbstractAcute graft-versus-host disease (GVHD) occurs in 40% to 60% of recipients of partially match...
International audienceAcute Graft-Versus-Host Disease (aGVHD), mediated by CD4(+) and CD8(+) effecto...
International audienceAcute graft-versus-host disease (aGVHD), mediated by CD4(+) and CD8(+) effecto...
CD4+CD25+FOXP3+ regulatory T cells (Treg) require activation through the T cell receptor for functio...
AbstractGraft-versus-host (GVH) disease (GVHD) continues to be a major life-threatening complication...
FoxP3(+) confers suppressive properties and is confined to regulatory T cells (T(reg)) that potently...
Regulatory T cells (Tregs) that constitu-tively express FOXP3 are instrumental to the maintenance of...
CD4(+)CD25(+) regulatory T cells (Tregs) are well known to suppress immunopathology induced in lymph...
AbstractNaturally arising CD4+CD25+ regulatory T cells (Tregs) have the potential to suppress aberra...
Background: CD4+ FoxP3+ regulatory T cells (Tregs) are the potent suppressors of activation and prol...
Induction of immunological tolerance to alloantigens would be the treatment of choice to prevent gra...
Allogeneic haematopoietic stem cell transplantation (alloHSCT) is an established therapy for many ha...
CD4+CD25+FOXP3+ regulatory T cells (Treg) require activation through the T cell receptor for functio...
International audienceThymus-derived regulatory T lymphocytes of CD4(+)CD25(+) phenotype regulate a ...
AbstractDonor bone marrow (BM)-derived CD4+CD25+ regulatory T cells, maturing in the host thymus, ar...
AbstractAcute graft-versus-host disease (GVHD) occurs in 40% to 60% of recipients of partially match...
International audienceAcute Graft-Versus-Host Disease (aGVHD), mediated by CD4(+) and CD8(+) effecto...
International audienceAcute graft-versus-host disease (aGVHD), mediated by CD4(+) and CD8(+) effecto...
CD4+CD25+FOXP3+ regulatory T cells (Treg) require activation through the T cell receptor for functio...
AbstractGraft-versus-host (GVH) disease (GVHD) continues to be a major life-threatening complication...
FoxP3(+) confers suppressive properties and is confined to regulatory T cells (T(reg)) that potently...
Regulatory T cells (Tregs) that constitu-tively express FOXP3 are instrumental to the maintenance of...
CD4(+)CD25(+) regulatory T cells (Tregs) are well known to suppress immunopathology induced in lymph...
AbstractNaturally arising CD4+CD25+ regulatory T cells (Tregs) have the potential to suppress aberra...
Background: CD4+ FoxP3+ regulatory T cells (Tregs) are the potent suppressors of activation and prol...
Induction of immunological tolerance to alloantigens would be the treatment of choice to prevent gra...
Allogeneic haematopoietic stem cell transplantation (alloHSCT) is an established therapy for many ha...
CD4+CD25+FOXP3+ regulatory T cells (Treg) require activation through the T cell receptor for functio...
International audienceThymus-derived regulatory T lymphocytes of CD4(+)CD25(+) phenotype regulate a ...
AbstractDonor bone marrow (BM)-derived CD4+CD25+ regulatory T cells, maturing in the host thymus, ar...
AbstractAcute graft-versus-host disease (GVHD) occurs in 40% to 60% of recipients of partially match...